Our Mission
Horizon Discovery (Horizon) is striving to provide researchers with the gold-standard tools that will accelerate the search for new and effective ‘targeted’ or ‘personalised’ medicines.
Central to realizing this ambition is the deployment of a proprietary gene-engineering technology called GENESIS that enables any endogenous gene in a human cell-line to be altered quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Using GENESIS, a wide panel of genetically-defined and patient-relevant X-MAN (Mutant And Normal) cell models have been developed and these are fast being adopted by academic and industry leaders to find and tailor the ‘right drugs’ to the ‘right patients’ based upon the unique genetic mutations that define their disease.
X-MAN cell-lines are now being used to rationalise every aspect of drug discovery pipelines; from the identification of more patient-relevant drug targets, to the design of shorter and less-costly clinical trials based upon the most likely patients most to respond to a given drug.